NeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Scientific Advisory Board

Core Insights - NeuroNOS has appointed Nobel Prize laureate Professor Dan Shechtman to its Scientific Advisory Board, enhancing its scientific expertise in developing treatments for Autism Spectrum Disorder (ASD) and Alzheimer's Disease (AD) [1][2] - The company utilizes a proprietary platform that integrates advanced behavioral techniques, AI, and wet lab capabilities to accelerate treatment development for complex neurological disorders [2][5] - NeuroNOS is on track to initiate first-in-human clinical trials for ASD in the United States in 2026, marking a significant step in its mission to transform treatment for affected individuals and families [2][4] Company Overview - NeuroNOS is focused on developing innovative therapies for neurodevelopmental and neurodegenerative disorders, particularly through small molecules that regulate Nitric Oxide (NO) levels in the brain [5] - Preclinical studies indicate elevated NO levels in children with ASD and adults with brain-related diseases, suggesting that managing NO levels is crucial for normal brain function [5] - The company collaborates with leading research institutions to advance medical innovation and deliver impactful treatments [5] Scientific Advisory Board - The addition of Professor Shechtman, alongside Professor Roger Kornberg, brings unparalleled scientific expertise to NeuroNOS, significantly enhancing its research capabilities [2][4] - Professor Shechtman is recognized for his groundbreaking discovery of quasicrystals and has decades of experience in materials science and structural chemistry [3] - His involvement is expected to elevate the scientific rigor at NeuroNOS and accelerate the development of effective treatments for ASD [4]